Company Performance - As of August 22, 2025, Fengcai Technology (688279) closed at 222.49 yuan, up 6.63% from the previous week's 208.65 yuan [1] - The stock reached a peak price of 230.86 yuan on August 22 and a low of 205.22 yuan on August 18 [1] - The current market capitalization is 25.346 billion yuan, ranking 58th out of 163 in the semiconductor sector and 724th out of 5,152 in the A-share market [1] Company Announcements - Fengcai Technology announced a series of important updates, including the results of the H-share special general meeting [2] - The company will undergo internal structural adjustments with key dates set: August 26, 2025, for important matters review; August 15, 2025, for the implementation of adjustments; and June 30, 2025, as another significant date [3] - A significant activity is planned for August 15, 2025, with details to be disclosed on August 27, 2025 [4] Financial Operations - Guotai Junan Securities has reviewed Fengcai Technology's plan to conduct foreign exchange hedging to mitigate currency fluctuation risks, with a funding limit of up to 1.5 billion yuan or equivalent foreign currency [5] - The hedging activities will include forward foreign exchange settlements, foreign exchange swaps, futures, and options, with a trading limit not exceeding the authorized amount at any point during the term [5] - The proposal for the foreign exchange hedging business has been approved by the board and will be submitted for shareholder approval [5] Shareholder Decisions - The 2025 equity incentive plan received overwhelming support, with 99.998% of A-share shareholders voting in favor and 97.3114% of H-share shareholders supporting the plan [6] - The total share capital as of August 15, 2025, is 113,919,380 shares, including 92,363,380 A-shares and 21,556,000 H-shares [6] - The company plans to issue 193,000 special A-shares [6]

Core Viewpoint - The company demonstrates resilience in a challenging OTC market, with a focus on growth in health consumer products and prescription drugs, while maintaining strong profitability and cash flow [1][2][3]. Group 1: Company Performance - In the first half of 2025, the company reported revenues of 2.14 billion yuan, a decrease of 6% year-on-year, while net profit attributable to shareholders increased by 6% to 520 million yuan [1]. - The second quarter of 2025 saw revenues of 960 million yuan, down 4% year-on-year, but net profit attributable to shareholders rose by 6% to 240 million yuan [1]. - The decline in revenue is primarily attributed to changes in OTC demand, but the company has optimized costs and expenses, leading to improved profitability [1]. Group 2: Industry Context - The pharmaceutical manufacturing industry in China faced a 1.2% decline in revenue and a 2.8% drop in profit in the first half of 2025 [2]. - OTC revenue for the company fell by 10% year-on-year to 1.55 billion yuan, while health consumer products grew by 17% to 230 million yuan, and prescription drug revenue increased by 7% to 360 million yuan [2]. Group 3: Profitability and Cash Flow - The gross margin for the first half of 2025 was 66.6%, a decrease of 2.4 percentage points year-on-year, mainly due to a lower proportion of high-margin OTC business [3]. - The company maintained a weighted average return on equity of 12.89%, an increase of 1.02 percentage points year-on-year, indicating sustained improvement in profitability [3]. - Operating cash flow net amount was 650 million yuan, while investment cash flow net amount was -330 million yuan, reflecting stable cash flow management [3]. Group 4: Dividend Policy - The company plans to distribute a cash dividend of 0.5 yuan per share, representing 60.78% of the net profit attributable to shareholders for the first half of 2025 [4]. - The company emphasizes high shareholder returns, maintaining a policy of two cash dividend distributions annually during the 14th Five-Year Plan period [4]. Group 5: Investment Outlook - The company maintains a profit forecast, expecting net profits attributable to shareholders of 897 million yuan, 1.015 billion yuan, and 1.145 billion yuan for 2025-2027, representing year-on-year growth of 14%, 13%, and 13% respectively [5]. - A target price of 29.96 yuan is set based on a 21x PE ratio for 2025, maintaining a "buy" rating [5].

Financial Performance - The company reported a total revenue of 5.296 billion yuan for the first half of 2025, representing a year-on-year increase of 31.31% [1] - The net profit attributable to shareholders reached 492 million yuan, up 28.07% year-on-year [1] - In Q2 2025, total revenue was 2.691 billion yuan, with a year-on-year growth of 26.66%, and net profit was 243 million yuan, increasing by 20.68% [1] Key Financial Ratios - Gross margin stood at 48.33%, a decrease of 0.79% compared to the previous year [1] - Net margin was 9.78%, down 2.85% year-on-year [1] - The ratio of selling, general, and administrative expenses to revenue was 31.72%, a decrease of 3.65% year-on-year [1] Accounts Receivable and Cash Flow - Accounts receivable amounted to 1.205 billion yuan, accounting for 173.23% of the net profit, indicating a significant receivables issue [2] - Operating cash flow per share increased by 77.62% to 0.58 yuan [1] Investment and Debt - The company’s interest-bearing debt rose to 2.084 billion yuan, an increase of 34.92% [1] - Cash and cash equivalents decreased by 60.88% to 1.532 billion yuan [1] Market Position and Growth Strategy - The company is focusing on high-potential product categories such as high-end dressings and surgical kits, aiming to establish a leading position in niche markets [7] - The domestic hospital business is expected to grow significantly, with strategies to enhance market share through competitive pricing and product promotion [8] Fund Management and Investor Interest - The company is held by a prominent fund manager, who has recently increased their stake, indicating strong investor confidence [2] - The largest fund holding the company is the "交银内需增长一年持有混合" fund, which has shown a significant increase in value over the past year [3]

Core Viewpoint -航亚科技's financial report for the first half of 2025 shows a revenue of 369 million yuan, an increase of 8.76% year-on-year, but a net profit attributable to shareholders decreased by 8.92% to 61.21 million yuan, primarily due to increased share-based payment expenses [3][4][8] Financial Performance - The company's revenue for the first half of 2025 was 369 million yuan, with a year-on-year growth of 8.76% [3] - The net profit attributable to shareholders was 61.21 million yuan, a decrease of 8.92% year-on-year [3] - The non-recurring net profit was 53.90 million yuan, down 18.35% year-on-year [3] - The increase in share-based payment expenses was the main reason for the decline in net profit [4][6] Expense Analysis - The company's operating expenses, referred to as "three fees," saw significant increases: sales expenses rose by 16.17%, management expenses by 40.12%, and financial expenses surged by 106.71% [4] - The increase in share-based payment expenses was a major contributor to the rise in sales and management expenses [4][6] Share-Based Payment Plan - The company implemented a restricted stock incentive plan in 2024, granting 5.5 million shares to incentivize management and align their interests with shareholders [5] - A high concentration of share grants was noted, with six core executives receiving 60% of the total shares allocated under the plan [6][7] Accounts Receivable Concerns - The company's accounts receivable reached 392 million yuan by the end of June 2025, exceeding its revenue for the first half of 2025 [8][9] - The accounts receivable as a percentage of revenue has increased significantly over the past three years, indicating a growing reliance on credit sales [8][9] - The company acknowledged the risks associated with high accounts receivable but noted that 95.45% of it was within one year, with clients being reputable aviation companies [8][10] Cash Flow Situation - Despite revenue growth, the net cash flow from operating activities decreased by 35.55% year-on-year, indicating potential liquidity issues [8][10]

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total amount ranging from RMB 30 million to 60 million, aimed at employee stock ownership plans or equity incentives [1][2][4]. Summary by Sections Repurchase Plan Overview - The repurchase amount is set between RMB 30 million and 60 million [1][2]. - The funding source for the repurchase will be the company's own funds [1][5]. - The maximum repurchase price is capped at RMB 25 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4]. - The repurchase will be conducted via centralized bidding [1][3]. - The duration for the repurchase is 12 months from the board's approval [1][3]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3][4]. - If the shares are not fully utilized for these purposes within three years, the company will follow the necessary procedures to cancel the unused shares and reduce registered capital accordingly [4][5]. Implementation and Conditions - The repurchase plan requires approval from at least two-thirds of the board members and does not need to be submitted to the shareholders' meeting [2][3]. - The estimated number of shares to be repurchased is between 120,000 and 240,000, representing 0.17% to 0.34% of the total share capital [2][4]. - The company will adjust the repurchase price if there are any capital changes, such as stock splits or dividends [4][5]. Financial Impact - The total amount for the repurchase represents approximately 1.10% of the company's total assets and 1.26% of the equity attributable to the parent company [5]. - The company asserts that the repurchase will not significantly impact its daily operations, financial status, research and development, profitability, or debt servicing capabilities [5][6]. Management and Compliance - The board has authorized the management to handle all matters related to the repurchase, including adjustments based on market conditions [7]. - There are no current plans for share reduction by directors, senior management, or major shareholders in the next three to six months [6][8].

北京市中伦（深圳）律师事务所 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 广东省深圳市福田区益田路 6003 号荣超中心 A 栋 8-10 层 邮编：518026 电话/Tel : +86 755 3325 6666 传真/Fax : +86 755 3320 6888/6889 www.zhonglun.com 关于兆易创新科技集团股份有限公司 第四个行权期行权条件及解除限售期解除限售条件 成就相关事项的 法律意见书 二〇二五年八月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 一、本所及本所经办律师根据《证券法》《律师事务所从事证券法律业 ...

Core Points - The company has proposed a 2024 Restricted Stock Incentive Plan aimed at enhancing corporate governance and aligning the interests of shareholders and management [1][6][10] - The plan involves granting a total of 2.34 million restricted shares, representing 2.15% of the company's total share capital of 108.92 million shares [2][12] - The grant price for the restricted shares is set at 9.52 RMB per share, which is below the average trading price prior to the announcement [17][18] - The plan is designed to attract and retain key management talent, ensuring alignment with the company's long-term development goals [6][23] Summary by Sections Purpose and Principles - The plan aims to establish a robust incentive mechanism to ensure the company's strategic goals are met while safeguarding shareholder interests [6][10] - It emphasizes the alignment of interests among shareholders, the company, and its management [6] Management Structure - The highest authority for the plan is the shareholders' meeting, which will approve the plan and any changes [7] - The board of directors is responsible for executing the plan, with oversight from the supervisory board [8] Incentive Objects - The plan targets three individuals: the board members and senior management, excluding independent directors and supervisors [9][12] - The selection of incentive objects is based on legal and performance criteria [9] Stock Source and Distribution - The restricted shares will be sourced from the company's repurchase from the secondary market or through targeted issuance [2][12] - The distribution of shares among the incentive objects is equal, with each receiving 78,000 shares [12] Validity and Granting Conditions - The plan is valid for a maximum of 48 months from the date of grant [13] - The granting of shares is contingent upon the approval of the shareholders' meeting and must occur within 60 days of approval [14] Vesting Arrangements - Shares will vest in three phases based on performance and tenure, with specific performance targets set for each phase [15][19] - The performance targets include net profit growth rates, with varying thresholds for each vesting period [19][23] Adjustment Mechanisms - The plan includes provisions for adjusting the number and price of shares in response to corporate actions such as stock splits or dividends [24][25] Accounting Treatment - The company will account for the stock options according to relevant accounting standards, estimating the fair value of the shares at the time of grant [26][27] - The estimated impact on net profit due to the stock option expenses is expected to be minimal compared to the potential positive effects on company performance [28] Handling Changes in Company or Incentive Objects - The plan will terminate if the company faces significant adverse events, with unvested shares being forfeited [29] - Changes in the status of incentive objects, such as job changes, will affect their eligibility for unvested shares [29]

Core Viewpoint - The company has announced the achievement of the second vesting conditions for its stock incentive plan, allowing for the vesting of 982,800 shares of restricted stock to eligible participants [1][13][21] Summary by Sections Stock Incentive Plan Overview - The stock incentive plan was initiated with a total of 87 million shares, with 8.12% allocated for the initial grant and 18.69% reserved for future grants [1][2] - The first grant consisted of 8.7 million shares, representing 81.31% of the total incentive plan [1] Vesting Conditions and Performance Targets - The vesting schedule includes three periods: 40% after 12 months, 30% after 24 months, and 30% after 36 months from the initial grant date [2][3] - The performance targets for the first vesting period require a net profit of 30 million yuan or a revenue increase of 30% for 2022 [3][4] - For the second vesting period, the targets are set at a net profit of 60 million yuan or a revenue increase of 60% for 2023 [4][5] Approval and Compliance - The board of directors and the supervisory board have approved the vesting conditions, confirming that the conditions have been met for the eligible participants [13][17] - The company has followed necessary procedures and disclosed information in compliance with relevant regulations [18][20] Impact on Financials - The vesting of 982,800 shares will increase the total share capital, potentially affecting earnings per share and return on equity [21] - The company does not anticipate significant impacts on its financial condition or operational results from this vesting [21]

Core Viewpoint - The company has announced a stock incentive plan involving the grant of 6.555 million restricted stocks, accounting for 1.58% of the total share capital, aimed at enhancing corporate governance and retaining talent [1][3][5]. Summary by Sections Stock Incentive Plan Purpose and Principles - The purpose of the incentive plan is to improve corporate governance, establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [1][3]. Stock Incentive Method and Source - The incentive method involves the issuance of second-class restricted stocks, sourced from repurchased shares or newly issued A-shares directed to incentive recipients [3][4]. Number of Rights Granted - The plan proposes to grant a total of 6.555 million restricted stocks, representing 1.58% of the company's total share capital of 41.56376 million shares [1][5]. Determination of Incentive Recipients - Incentive recipients include directors, senior management, core technical personnel, and key business staff, excluding independent directors and supervisors [4][5]. Distribution of Restricted Stocks - The distribution of restricted stocks among recipients is detailed, with 97.25% allocated to business backbone personnel [5]. Validity Period of the Incentive Plan - The plan is valid from the date of stock grant until all granted stocks are vested or become invalid, with a maximum duration of 36 months [6]. Granting and Vesting Conditions - The grant price for the restricted stocks is set at 26.15 yuan per share, with specific conditions for granting and vesting based on performance metrics [9][10]. Performance Assessment Metrics - The performance assessment will consider revenue growth excluding impacts from public health events, with specific targets set for the years 2024 and 2025 [12][13]. Accounting Treatment and Impact on Financial Performance - The plan's implementation will affect the company's accounting costs, with estimated expenses to be amortized over the vesting period [23][24]. Rights and Obligations of the Company and Recipients - The company retains the right to cancel unvested stocks if performance conditions are not met, while recipients must fulfill tax obligations related to the granted stocks [25][26].

证券简称：华大智造 证券代码：688114 深圳华大智造科技股份有限公司 2024 年限制性股票激励计划（草案修订稿） 声 明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈 述或者重大遗漏，导致不符合授予权益或权益归属安排的，激励对象应当自相 关信息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激 励计划所获得的全部利益返还公司。 深圳华大智造科技股份有限公司 2024 年限制性股票激励计划（草案修订稿） 特别提示 一、本激励计划系依据《中华人民共和国公司法》《中华人民共和国证券 法》《上海证券交易所科创板股票上市规则》《上市公司股权激励管理办法》 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》和其他有关法 律、法规、规范性文件，以及《深圳华大智造科技股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）。股 票来源为深圳华大智造科技股份有限公司（以下简称"公司"或"本公司"） 从二级市场回购或/ ...